Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved multiple immune-related conditions in one patient.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Belatacept may be a promising treatment for alopecia areata.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.

Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Combining Proton Minibeam with FLASH Radiotherapy may improve cancer treatment by reducing side effects and increasing effectiveness.

YH0618 helps reduce chemotherapy-induced hair loss by targeting specific proteins and pathways.

The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Photobiomodulation helps protect hair follicle cells from damage caused by DHT.

Selenium shows promise in preventing and controlling prostate cancer.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.

Targeting PTEN can improve healing in venous leg ulcers.

Lower TNF-α levels in PRP may predict better treatment outcomes for bladder conditions.

Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.

Thymosin beta 4 protects cells from damage by blocking a harmful microRNA and boosting a protective gene.